Organization
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
31 abstracts
1 poster
Abstract
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.Org: UT Health San Antonio, San Antonio, TX, The Ohio State University, Columbus, OH, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, University of Chicago Medical Center, Chicago, IL, SWOG Cancer Research Network, San Antonio, TX,
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).Org: University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium, Oregon Health & Science University, Portland, OR, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, Germany,
Abstract
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain, Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany,
Abstract
Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC).Org: The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX,
Abstract
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.Org: Centre Hospitalier De L Ardenne, Libramont-Chevigny, Belgium, Hospital Universitario Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Lleida, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, The Oncology Institute, Whittier, CA,
Abstract
Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Investigational Cancer Therapeutics Department, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).Org: Rush University Medical Center, NRG Oncology SDMC/ACR, Mount Sinai Medical Center, University of Maryland, Baltimore, MD, Brown University School of Medicine-Rhode Island Hospital,
Abstract
A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Org: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Centre Hospitalier Régional Universitaire de Nîmes, Hopital Cochin, Groupement des Hôpitaux de l'Institut Catholique de Lille,
Abstract
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.Org: Bristol Myers Squibb, Oncosite Centro de Pesquisa Clínica em Oncologia, Puerta de Hierro University Hospital, Madrid, Spain, Dana-Farber Cancer Institute, Boston, MA, USA, McGill University Health Centre, Montreal, QC, Canada,
Abstract
Impact of boarding time on in-hospital mortality in patients with cancer presenting to the emergency department.Org: The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Abuse potential and analgesic efficacy of different IV opioid infusion rates among patients hospitalized with cancer pain: A randomized crossover trial.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Addressing misinformation about cancer care in the clinical setting: A pilot study of a conversation guide and training for cancer care providers.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Inpatient outcomes of patients with new solid tumors admitted to a comprehensive cancer center.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Single center experience of IDH inhibitors in high-grade gliomas.Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.Org: Department of Surgery, University of California, San Francisco, San Francisco, CA, Department of Medicine, University of California, San Francisco, San Francisco, CA, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Weill Cornell Medicine Department of Population Health Sciences, New York, NY, University of California, San Francisco Department of Surgery, San Francisco, CA,
Abstract
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas Southwestern Medical Center, Dallas, TX, Stanford Cancer Center GI Surgical Oncology, Stanford, CA, Cedars-Sinai Cancer Institute, Los Angeles, CA, Cedars-Sinai Medical Center, Los Angeles, CA,
Abstract
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, Jiangsu Province Hospital, Nanjing, China, Winship Cancer Institute, Atlanta, GA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Henan Cancer Hospital, Zhengzhou, China,
Abstract
A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach.Org: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, MD Anderson Cancer Center, Houston, TX, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.Org: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.Org: National University Cancer Institute, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, National Cancer Centre Singapore, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, UCHealth Cancer Care-Anschutz Medical Campus-University of Colorado Cancer Center, Aurora, CO,
Abstract
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Cellenkos Inc, Houston, TX, Incyte Corporation, Genève, Switzerland,
Abstract
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.Org: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, The Clatterbridge Cancer Centre and University of Liverpool, Liverpool, United Kingdom, Intermountain Medical Center, Murray, UT, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA,
Abstract
KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.Org: Faculty of Medicine University Medical Center and Princess Máxima Center, Utrecht, the Netherlands, Comprehensive Cancer Center Munich and Technical University Munich & Ludwig Maximilian University, Munich, Netherlands, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), and German Cancer Consortium, Partner Site Essen, Essen, Germany, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy,
Abstract
Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy.Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Jacksonville, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University of Texas MD Anderson Cancer Center, Houston, TX,